ClinVar Miner

Submissions for variant NM_000157.4(GBA1):c.247C>T (p.Arg83Cys)

gnomAD frequency: 0.00002  dbSNP: rs1141812
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
CeGaT Center for Human Genetics Tuebingen RCV000994119 SCV001147444 uncertain significance not provided 2017-05-01 criteria provided, single submitter clinical testing
GeneDx RCV000994119 SCV001768386 uncertain significance not provided 2021-07-22 criteria provided, single submitter clinical testing Reported previously using alternate nomenclature (R44C) in an Ashkenazi Jewish (AJ) individual with essential tremor; however, the authors concluded that there was no evidence for association of GBA variants with essential tremor as the variants were present with similar frequencies in AJ essential tremor patients and AJ controls (Clark et al., 2010); Reported in the heterozygous state in two individuals with Parkinson disease and was absent in controls. One of the individuals was a Parkinson disease patient with no family history who also harbored a variant in the LRRK2 gene (Benitez et al., 2016); In an Ashkenazi Jewish population screening study for GBA variants in Parkinson patients, the frequency of the R83C (reported as R44C) variant was 4 times higher in an in-house control population (7/662) than in the Parkinson disease patient population (2/735); however, the variant was present at a lower frequency in a larger control population derived from the IBD exomes project, suggesting that further studies are needed to better understand the significance of this variant (Ruskey et al., 2018); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Missense variants in nearby residues reported in the Human Gene Mutation Database in individuals with Gaucher disease and Parkinson disease (Stenson et al., 2014) This variant is associated with the following publications: (PMID: 31996268, 29842932, 19815695, 19527940, 27094865, 26117366, 21837367)
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001779099 SCV002014961 uncertain significance not specified 2021-10-18 criteria provided, single submitter clinical testing Variant summary: GBA c.247C>T (p.Arg83Cys), also known as R44C in literatures, results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8.5e-05 in 258476 control chromosomes (gnomAD and publication data). This frequency is not significantly higher than expected for a pathogenic variant in GBA causing Gaucher Disease (8.5e-05 vs 0.005), allowing no conclusion about variant significance. c.247C>T has been reported in the literature in individuals affected with essential tremor, Amyotrophic lateral sclerosis, Dementia with Lewy bodies and Parkinson's disease (Clark_2009, Gan-Or2011, Alcalay_2015, Mata_2016, Benitez_2016, Kruger_2016, Robak_2017, Goldstein_2019, Orme_2020, Mangone_2020). These reports do not provide unequivocal conclusions about association of the variant with disease. Additionally, other missense variants (p.R78H, p.S81N,p.G85E, p.T100M) in nearby residues have been found in individuals affected with Gaucher disease and Parkinson's disease in the Human Gene Mutation Database. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
Fulgent Genetics, Fulgent Genetics RCV002479164 SCV002782471 uncertain significance Lewy body dementia; Gaucher disease type I; Gaucher disease type II; Gaucher disease type III; Gaucher disease perinatal lethal; Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome; Parkinson disease, late-onset 2022-05-03 criteria provided, single submitter clinical testing
Natera, Inc. RCV001832312 SCV002086483 uncertain significance Gaucher disease 2017-08-09 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.